Qiagen Completes SAB Buy; Added to Nasdaq-100 | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen has completed its acquisition of SABiosciences, a privately held developer of disease- and pathway-focused PCR assay panels, for around $90 million.

Qiagen announced the deal in early November, saying at that time that it expects SABiosciences' products to be highly synergistic with its September acquisition of UK-based companion diagnostics firm DxS.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.